South Korea · Delayed Price · Currency is KRW Neuromeka Statistics
Total Valuation
Neuromeka has a market cap or net worth of KRW 705.88 billion. The enterprise value is 741.18 billion.
| Market Cap | 705.88B |
| Enterprise Value | 741.18B |
Important Dates
The last earnings date was Thursday, March 26, 2026.
| Earnings Date | Mar 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Neuromeka has 12.36 million shares outstanding. The number of shares has increased by 6.54% in one year.
| Current Share Class | 12.36M |
| Shares Outstanding | 12.36M |
| Shares Change (YoY) | +6.54% |
| Shares Change (QoQ) | +0.30% |
| Owned by Insiders (%) | 18.50% |
| Owned by Institutions (%) | 15.55% |
| Float | 10.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 37.24 |
| PB Ratio | 50.80 |
| P/TBV Ratio | 51.58 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -33.73 |
| EV / Sales | 39.10 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -51.08 |
Financial Position
The company has a current ratio of 0.55, with a Debt / Equity ratio of 3.85.
| Current Ratio | 0.55 |
| Quick Ratio | 0.33 |
| Debt / Equity | 3.85 |
| Debt / EBITDA | n/a |
| Debt / FCF | -3.69 |
| Interest Coverage | -2.81 |
Financial Efficiency
Return on equity (ROE) is -177.61% and return on invested capital (ROIC) is -13.87%.
| Return on Equity (ROE) | -177.61% |
| Return on Assets (ROA) | -9.95% |
| Return on Invested Capital (ROIC) | -13.87% |
| Return on Capital Employed (ROCE) | -66.65% |
| Weighted Average Cost of Capital (WACC) | 19.30% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.20 |
| Inventory Turnover | 1.87 |
Taxes
In the past 12 months, Neuromeka has paid 66.31 million in taxes.
| Income Tax | 66.31M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +166.20% in the last 52 weeks. The beta is 2.89, so Neuromeka's price volatility has been higher than the market average.
| Beta (5Y) | 2.89 |
| 52-Week Price Change | +166.20% |
| 50-Day Moving Average | 74,514.00 |
| 200-Day Moving Average | 40,818.00 |
| Relative Strength Index (RSI) | 40.73 |
| Average Volume (20 Days) | 246,422 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Neuromeka had revenue of KRW 18.95 billion and -21.97 billion in losses. Loss per share was -1,956.00.
| Revenue | 18.95B |
| Gross Profit | 3.32B |
| Operating Income | -14.86B |
| Pretax Income | -21.92B |
| Net Income | -21.97B |
| EBITDA | -12.02B |
| EBIT | -14.86B |
| Loss Per Share | -1,956.00 |
Balance Sheet
The company has 18.23 billion in cash and 53.52 billion in debt, with a net cash position of -35.30 billion or -2,855.18 per share.
| Cash & Cash Equivalents | 18.23B |
| Total Debt | 53.52B |
| Net Cash | -35.30B |
| Net Cash Per Share | -2,855.18 |
| Equity (Book Value) | 13.89B |
| Book Value Per Share | 1,219.81 |
| Working Capital | -31.03B |
Cash Flow
In the last 12 months, operating cash flow was -11.36 billion and capital expenditures -3.15 billion, giving a free cash flow of -14.51 billion.
| Operating Cash Flow | -11.36B |
| Capital Expenditures | -3.15B |
| Depreciation & Amortization | 2.83B |
| Net Borrowing | 2.97B |
| Free Cash Flow | -14.51B |
| FCF Per Share | -1,173.84 |
Margins
Gross margin is 17.52%, with operating and profit margins of -78.38% and -115.93%.
| Gross Margin | 17.52% |
| Operating Margin | -78.38% |
| Pretax Margin | -115.67% |
| Profit Margin | -115.93% |
| EBITDA Margin | -63.44% |
| EBIT Margin | -78.38% |
| FCF Margin | n/a |
Dividends & Yields
Neuromeka does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.54% |
| Shareholder Yield | -6.54% |
| Earnings Yield | -3.11% |
| FCF Yield | -2.06% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Neuromeka has an Altman Z-Score of 0.6 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.6 |
| Piotroski F-Score | 3 |